With its ability to alter NF-κB signaling for reduction in cytokine secretion potentially targeting the cytokine storm, improve defense by increasing the IFNγ production for increased antiviral defense and improve expansion of CD4+ T-cells thus targeting the lymphocytopenia, allicin is a promising natural immunomodulatory adjuvant that can be used in conjunction with antiviral therapy in COVID-19 patients. This evidence concerns the gene CD4 and lymphopenia.